# S&P 500

Type: index

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/sp-500
Canonical HTML page: https://getbiobrief.com/entity/sp-500

## Timeline

- **2026-08-05**: Moderna flu vaccine PDUFA date — FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
- **2025-12**: Axsome full-year 2025 results — Annual revenue more than doubles to $617.1 million, with Auvelity net product revenue up 68% year over year.
- **2025-06**: Revolution Medicines mid-2025 data readout — RMC-6236 shows nearly 90% tumor response in an early-phase pancreatic cancer study, driving stock surge.

## Recent coverage (2 stories)

### Moderna's PDUFA Aug 5 Looms as 3 Biotechs Return Up to 230% in H1 2026
2026-07-07 06:57:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
Full story: https://getbiobrief.com/story/biotech-outperform-moderna-pdufa-revolution-axsome

### Pfizer’s R&D Setback: Abandoned GLP-1 Drug Leaves 130% Payout Ratio at Risk
2026-06-28 01:10:18 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Pfizer’s 2025 GLP-1 failure underscores a faltering pipeline just as generational patent cliffs approach. The 130% dividend payout ratio highlights the financial strain of recent R&D misses, challenging the biotech giant’s turnaround narrative.
Full story: https://getbiobrief.com/story/pfizer-glp-1-failure-dividend-sustainability-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.